Innovation & Technology for Biosimilar Development

A biosimilar is an organic item very like an affirmed natural item, known as a kind of perspective item, with no clinically significant contrasts as far as wellbeing and viability. In the U.S., if a natural compound exhibits practically identical information to a U.S. Nourishment and Drug Administration (FDA)- authorized item from expository, preclinical and clinical reviews, it will be acknowledged as a biosimilar after termination of trend-setter licenses through a curtailed course. Tradable natural items are likewise biosimilars, however should meet extra criteria to coordinate the reference item. Interchangeable can be substituted for the reference item without a medicine from a social insurance supplier.

  • Biosimilar Product Reimbursement and Pricing
  • Biosimilar Regulatory Updates and Legal Implications
  • Biosimilar Market Access and Commercialization

Related Conference of Innovation & Technology for Biosimilar Development

June 08-09, 2018

7th International conference on Pharmaceutical Auditing

Baltimore, Maryland, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
August 15-17, 2018

8th World Congress Spectroscopy and Analytical Techniques

Stockholm, Sweden
September 18-19, 2018

6th European Biopharma Congress

Amsterdam, Netherlands

Innovation & Technology for Biosimilar Development Conference Speakers

Recommended Sessions

Related Journals

Are you interested in